Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results

18:45 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results on Wednesday, March 1st for the fiscal quarter ended December 31, 2016. The Corporation’s unaudited fiscal Q3 2017 condens...

Other Sources for this Article

Antibe Therapeutics Inc.
Dan Legault, 416-473 4095
Chief Executive Officer


More From BioPortfolio on "Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Dentistry is the study, management and treatment of diseases and conditions affecting the mouth, jaw, teeth and their supporting tissues (Oxford Medical Dictionary) The work of a dentist ranges from regular patient check-up to orthodontics and surgery....